Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 03:05PM GMT
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

So thanks for being here everybody. We're going to get started with the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley, and pleased to have Sarepta.

Just quickly before I get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up a copy at the registration desk.

So very pleased to have with me Doug Ingram, who is the President and CEO of Sarepta. Doug, I don't know if you want to make any opening comments, but if not, we'll jump right in.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Sure. Well first, let me say this because I've been reminded I have to mention our forward-looking statements. Obviously, we'll be talking about things that are going to happen in the future. There

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot